About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Enrolling By InvitationNCT03474237

A Prospective Cohort Study for Patients With Adrenal Diseases

The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.

Lead sponsor: Seoul National University Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Seoul National University Hospital

The investigators will recruit 150 patients annually for 10 years (adrenal incidentaloma 100 patients, pheochromocytoma 15 patients, primary aldosteronism 25 patients, adrenal cushing syndrome 10 patients, adrenocortical carcinoma 2 patients) and perform hormonal, biochemical, imaging exam according to each disease's clinical guidelines. Based on this, the investigators will identify pathologic features, complications, and prognostic factors of each disease.

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults, male or female aged 19 years or older
•newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma

Exclusion Criteria

•previous or current history of adrenal diseases
•using oral or intravenous steroids
•history of major depressive disorder
•history of chronic alcoholics
•history of any cancer with suspicious adrenal metastasis
•those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)

Related studies

RECRUITINGPhase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

NCT03206060 · Pheochromocytoma, Paraganglioma, and more

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 1/2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

NCT05636618 · Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, and more

RECRUITINGPhase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146 · Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), and more

RECRUITINGPhase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 18, 2020Terms

Trial snapshot

StatusENROLLING_BY_INVITATION

Phase—

Enrollment1,500

Start dateOct 2018

Last updatedMar 18, 2020

Condition

Adrenal Adenoma Cushing Syndrome Pheochromocytoma Adrenal Incidentaloma Adrenocortical Carcinoma+1 more

Locations shown

Seoul National University Hospital

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions